Press Releases March 30, 2026 08:00 PM

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB576 Million in 2026

KANZHUN LIMITED Advances Share Repurchase Program, Spending Over RMB576 Million in 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED (BOSS Zhipin) announced the continuation of its share repurchase program, having spent approximately RMB34.5 million to buy back 744,334 shares on March 30, 2026. Total repurchases for the year so far exceed RMB576 million, demonstrating the company's focus on enhancing shareholder value.

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB576 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has repurchased over RMB576 million worth of shares year-to-date in 2026.
  • The company repurchased 744,334 ordinary shares on March 30 using RMB34.5 million.
  • The ongoing share buyback program highlights management's commitment to returning value to shareholders.
  • The company's actions impact the technology and internet sectors, particularly online recruitment and HR services markets.

BEIJING, March 31, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB34.5 million to repurchase 744,334 ordinary shares on March 30. Year-to-date in 2026, the Company has deployed over RMB576 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued allocation of funds to share repurchases may limit capital available for business expansion or R&D.
  • Market volatility could affect the timing and scale of repurchases.
  • Changes in regulatory environment affecting stock buybacks could impact the program.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026